Apollomics Inc. Warrant

Healthcare US APLMW

0.013USD
0.0066(103.12%)

Last update at 2024-10-15T17:58:00Z

Day Range

0.010.02

LowHigh

52 Week Range

0.010.13

LowHigh

Fundamentals

Previous Close 0.0064
Market Cap37.35M
Volume55445
P/E Ratio-
Dividend Yield-%
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM 0.00000M
Diluted EPS TTM-

Overview
Financials
Peer Comparison
Reports
Stock Research & News

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31
Income before tax	-240.81000M	-94.79600M	-74.90500M
Minority interest	-	-	-
Net income	-240.81100M	-94.79700M	-74.82000M
Selling general administrative	9.95M	15.29M	11.04M
Selling and marketing expenses	-	-	-
Gross profit	-	-	-
Reconciled depreciation	0.78M	0.68M	0.61M
Ebit	-	-	-
Ebitda	-239.94200M	-94.03200M	-74.22400M
Depreciation and amortization	-	-	-
Non operating income net other	-	-	-
Operating income	-44.38800M	-50.27200M	-40.75400M
Other operating expenses	-	-	-
Interest expense	0.09M	0.08M	0.07M
Tax provision	0.00100M	0.00100M	-0.08500M
Interest income	0.43M	0.47M	0.33M
Net interest income	0.34M	0.38M	-3.52400M
Extraordinary items	-	-	-
Non recurring	-	-	-
Other items	-	-	-
Income tax expense	-	-	-
Total revenue	0.00000M	0.00000M	0.00000M
Total operating expenses	44.39M	50.27M	40.75M
Cost of revenue	-	-	-
Total other income expense net	-196.76000M	-44.90800M	-30.62700M
Discontinued operations	-	-	-
Net income from continuing ops	-240.81100M	-94.79700M	-74.82000M
Net income applicable to common shares	-	-	-
Preferred stock and other adjustments	-	-	-

Breakdown	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly
Date	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total assets	55.39M	76.47M	123.44M	169.94M
Intangible assets	14.76M	14.78M	14.80M	10.32M
Earning assets	-	-	-	-
Other current assets	-	-	-	-
Total liab	14.15M	524.60M	336.30M	297.87M
Total stockholder equity	41.23M	-448.12000M	-212.86200M	-127.93300M
Deferred long term liab	-	-	-	-
Other current liab	-	0.07M	1.65M	3.25M
Common stock	-	-	-	-
Capital stock	0.00900M	0.04M	0.04M	0.04M
Retained earnings	-646.96500M	-474.60000M	-235.43500M	-141.54300M
Other liab	-	-	-	-
Good will	-	-	-	-
Other assets	-	-	-	-
Cash	32.06M	32.67M	46.74M	130.65M
Cash and equivalents	-	-	-	-
Total current liabilities	13.56M	12.36M	13.56M	12.08M
Current deferred revenue	-	-	-	-
Net debt	-	-	-	-
Short term debt	-	-	-	-
Short long term debt	4.24M	-	-	-
Short long term debt total	-	-	-	-
Other stockholder equity	-	-	-	-
Property plant equipment	-	-	-	-
Total current assets	39.92M	55.79M	99.37M	157.66M
Long term investments	0.00000M	4.31M	7.84M	0.00000M
Net tangible assets	-	-	-	-
Short term investments	5.76M	21.94M	47.74M	23.74M
Net receivables	-	-	-	-
Long term debt	-	-	-	-
Inventory	-	-	-	-
Accounts payable	-	-	-	-
Total permanent equity	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-
Accumulated other comprehensive income	-	-	-	-
Additional paid in capital	-	-	-	-
Common stock total equity	-	-	-	-
Preferred stock total equity	-	-	-	-
Retained earnings total equity	-	-	-	-
Treasury stock	-	-	-	-
Accumulated amortization	-	-	-	-
Non currrent assets other	-	-	-	-
Deferred long term asset charges	-	-	-	-
Non current assets total	15.46M	20.68M	24.07M	12.28M
Capital lease obligations	0.42M	0.99M	1.04M	1.51M
Long term debt total	-	-	-	-

Breakdown	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31
Investments	29.05M	-38.95000M	2.33M
Change to liabilities	-	-	-
Total cashflows from investing activities	-	-	-
Net borrowings	-	-	-
Total cash from financing activities	-0.29400M	-1.64300M	125.51M
Change to operating activities	-	-	-
Net income	-240.81100M	-94.79700M	-74.82000M
Change in cash	-14.06500M	-83.90500M	92.16M
Begin period cash flow	46.74M	130.65M	38.49M
End period cash flow	32.67M	46.74M	130.65M
Total cash from operating activities	-42.82400M	-43.31200M	-35.68100M
Issuance of capital stock	0.39M	0.14M	6.03M
Depreciation	0.78M	0.68M	0.61M
Other cashflows from investing activities	-	-	-
Dividends paid	0.00000M	0.00000M	0.00000M
Change to inventory	-	-	-
Change to account receivables	-	-	-
Sale purchase of stock	-	-	-
Other cashflows from financing activities	-	-	-
Change to netincome	-	-	-
Capital expenditures	0.37M	7.55M	10.14M
Change receivables	-	-	-
Cash flows other operating	-	-	-
Exchange rate changes	-	-	-
Cash and cash equivalents changes	-	-	-
Change in working capital	6.49M	2.64M	3.06M
Stock based compensation	3.58M	8.12M	4.51M
Other non cash items	186.75M	-0.38400M	3.52M
Free cash flow	-43.19100M	-50.86200M	-45.82500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
APLMW Apollomics Inc. Warrant	0.0066 103.12%	0.01	-	-	-	0.04	-0.1196
NVO Novo Nordisk A/S	-2.22 1.85%	117.56	41.58	31.15	2.13	32.99	2.11	4.70
NONOF Novo Nordisk A/S	-0.45 0.38%	119.55	41.06	31.25	2.08	33.11	2.11	4.70
VRTX Vertex Pharmaceuticals Inc	-1.745 0.36%	483.07	29.67	24.33	10.38	5.83	9.33	20.00
REGN Regeneron Pharmaceuticals Inc	0.10 0.0099%	1014.35	29.07	20.12	7.57	3.82	6.95	19.42

Reports Covered

View All

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.